(Q36486949)

14 August 2017

1 reference

title

Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure (English)

1 reference

14 August 2017

Antiestrogen therapy for breast cancer: Current strategies and potential causes for therapeutic failure (English)

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

author name string

Y. Iino

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672078

25 October 2022

D. F. Gibson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672078

25 October 2022

V. C. Jordan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1672078

25 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1672078

25 October 2022

publication date

1 January 1991

1 reference

full work available at URL

14 August 2017

http://link.springer.com/content/pdf/10.1007/978-1-4615-3940-7_10.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Cancer Treatment and Research

25 October 2022

published in

1 reference

14 August 2017

53

1 reference

14 August 2017

221-237

1 reference

A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol

14 August 2017

1

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Postcoital contraception

2

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Antioestrogens. A review

3

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens

25 October 2022

6

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Pharmacological Reviews

7

36

245

VC Jordan

1984

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Antiestrogens in the treatment of breast cancer

25 October 2022

12

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

The pharmacology and clinical uses of tamoxifen

25 October 2022

13

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Cancer Treatment Reports

16

64

745

VC Jordan

1980

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors

25 October 2022

18

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen

25 October 2022

22

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

25 October 2022

25

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

25 October 2022

27

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

25 October 2022

29

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study

25 October 2022

30

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

25 October 2022

32

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial

25 October 2022

33

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Corticosteroid induced osteoporosis and hormone implants

25 October 2022

35

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Postmenopausal oestrogen treatment and stroke: a prospective study

25 October 2022

36

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Menopausal oestrogen therapy and protection from death from ischaemic heart disease

25 October 2022

37

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Oestrogen-like effect of tamoxifen on vaginal epithelium

25 October 2022

38

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women

25 October 2022

39

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estrogen-Like Action of Tamoxifen on Vaginal Epithelium in Breast Cancer Patients

25 October 2022

41

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Effects of anti-estrogens on bone in castrated and intact female rats

25 October 2022

42

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years

25 October 2022

43

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

25 October 2022

44

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Severe lipemia induced by tamoxifen

25 October 2022

45

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Preliminary report on the use of tamoxifen in the treatment of endometriosis

25 October 2022

47

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Tamoxifen in advanced endometrial carcinoma

25 October 2022

48

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma

25 October 2022

49

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Cancer Treatment Reports

50

64

805

KD Swenerton

1980

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

25 October 2022

51

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Tamoxifen and endometrial cancer

25 October 2022

52

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women

25 October 2022

56

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party

25 October 2022

58

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes

25 October 2022

61

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Autocrine secretion and malignant transformation of cells.

25 October 2022

63

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

64

33

375

ME Lippman

1985

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma

25 October 2022

65

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells

25 October 2022

66

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene

25 October 2022

67

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor

25 October 2022

69

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure

25 October 2022

70

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells

25 October 2022

71

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Anti-oestrogen action in experimental breast cancer.

25 October 2022

75

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

A new triphenylethylene compound, Fc-1157a. I. Hormonal effects

25 October 2022

76

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

25 October 2022

77

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model

25 October 2022

78

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma

25 October 2022

80

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

25 October 2022

81

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Tamoxifen and liver damage

25 October 2022

87

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer

25 October 2022

88

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Binding of toremifene to human serum proteins

25 October 2022

90

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Influence of antiestrogen drugs on the sex hormone and sex hormone-binding globulin levels in breast cancer patients

25 October 2022

91

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

93

63

187

L Kargas

1985

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen

25 October 2022

94

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Journal of the National Cancer Institute

25 October 2022

95

71

55

W Roos

1983

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.

25 October 2022

96

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus

25 October 2022

97

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Development of new drugs for endocrine tumour chemotherapy

25 October 2022

98

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat

25 October 2022

99

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors

25 October 2022

100

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Massive estrogen administration in premenopausal women with metastatic breast cancer

25 October 2022

103

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Estrogen Inhibition of Mammary Tumor Growth in Rats; Counteraction by Prolactin

25 October 2022

104

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

Fundamental research leading to improved endocrine therapy for breast cancer

25 October 2022

105

1 reference

https://api.crossref.org/works/10.1007/978-1-4615-3940-7_10

25 October 2022

Identifiers

0 references

1 reference